European Archives - Page 702 of 1175 - European Medical Journal

Continue
8 Mins
30 Jul 2020

EHA 2020 Interview: Roundtable Interview with Dr Alba Maiques-Diaz and Dr Anna Kabanova

Roundtable interview with Dr Alba Maiques-Diaz and Dr Anna Kabanova
hematology 8.1 featured image
2 Mins
30 Jul 2020

Paused Transcription: A Novel MIR139-Silencing Mechanism Downstream of MLL-AF9 in Acute Myeloid Leukaemia

The expression and tight regulation of microRNA is essential for haematopoiesis and the prevention of leukaemia…
Doing More for Patients with Immune Thrombocytopenia
9 Mins
30 Jul 2020

Doing More for Patients with Immune Thrombocytopenia: Putting New Recommendations into Practice

The American Society of Hematology (ASH) guidelines and the International Consensus Report (ICR) recommendations were first published in 2010 and 2011…
hematology 8.1 featured image
August 2020

EMJ Hematology 8.1 2020

Featuring an independent review of the European Hematology Association (EHA) Virtual Congress 2020, alongside excellent articles presenting clinical…
hematology 8.1 featured image
2 Mins
30 Jul 2020

Gene Therapy For Fanconi Anaemia: A Report on Outcomes in Nine Patients

Fanconi anaemia (FA) is a rare, inherited bone marrow failure syndrome, for which the only available curative treatment is haematopoietic cell transplant…
hematology 8.1 featured image
10 Mins
30 Jul 2020

Outcomes for Patients with High-Risk Acute Myeloid Leukaemia: Can We Move from Months to Years?

This symposium focussed on the recognition of, and treatment options for, high-risk AML. Prof Cluzeau considered universal or targeted treatment…
AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study
2 Mins
30 Jul 2020

AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukaemia and an IDH1 Mutation

Isocitrate dehydrogenase 1 (IDH1) is a metabolic enzyme which catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate…
hematology 8.1 featured image
2 Mins
30 Jul 2020

Implementation of Haematological Malignancies Patient-Reported Outcome Measure in Clinical Practice: Haematologists’ Experience

Patients with haematological malignancies (HM) may experience significantly compromised quality of life (QoL) as a result of the disease and its…
hematology 8.1 featured image
2 Mins
30 Jul 2020

Integrative Analysis of the Genomic Landscape of Hodgkin Lymphoma Using Liquid Biopsies

The genomic landscape of Hodgkin lymphoma (HL) is not well understood because of the scarcity of Hodgkin-Reed–Sternberg cells, which makes conventional…
Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib
3 Mins
30 Jul 2020

Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib, with the BCL2-Inhibitor Venetoclax +/-Azacitidine in IDH1-Mutated Myeloid Malignancies

Venetoclax is a potent, selective, oral inhibitor of B-cell lymphoma-2. It is approved in the USA in combination with azacitidine, decitabine…
We’ve noticed you’re accessing
from North/South America.